Evidence map›Paper›PMID 27796865›Full record

ReviewCurrent cardiology reports2016

Hypertension in Patients with Heart Failure with Reduced Ejection Fraction.

Massimo Volpe, Caterina Santolamazza, Giuliano Tocci

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current cardiology reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Massimo VolpeCardiology Unit, Department of Clinical and Molecular Medicine, School of Medicine and Psychology, University Sapienza of Rome, S. Andrea Hospital, Rome, Italy. massimo.volpe@uniroma1.it.
Caterina SantolamazzaCardiology Unit, Department of Clinical and Molecular Medicine, School of Medicine and Psychology, University Sapienza of Rome, S. Andrea Hospital, Rome, Italy.
Giuliano TocciCardiology Unit, Department of Clinical and Molecular Medicine, School of Medicine and Psychology, University Sapienza of Rome, S. Andrea Hospital, Rome, Italy.
Istituto Neurologico Mediterraneo · ITSapienza University of Rome · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypertension (HTN) is a well-known health problem associated with considerable morbidity and mortality and it is an important risk factor for the development of heart failure (HF). These findings support the need for optimizing the antihypertensive strategies to prevent the progression to HF. Interestingly, the progression from HTN to HF, among other things, may be a consequence of inappropriate over-activation of the renin-angiotensin-aldosterone system (RAAS), sympathetic nervous system (SNS), and the natriuretic peptide system (NPS). In the present review, we will discuss the pathophysiological aspects of the progression from HTN to HF with reduced ejection fraction (HFrEF) and we will focus on the evolution of different pharmacological therapies which are reported to be effective in reducing BP and improving HF outcomes, paying particular attention to the recent trials that have demonstrated the efficacy of the combined therapy of RAAS blockade and Neprilysin (NEP) inhibitor in lowering BP and mediating several beneficial actions within cardiovascular tissues, such as avoiding the worsening of HF.

Indexed as

Angiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAntihypertensive AgentsCardiovascular AgentsDisease ProgressionHeart FailureHumansHypertensionNeprilysinRenin-Angiotensin SystemRenin InhibitorsAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAntihypertensive AgentsCardiovascular AgentsNeprilysinRenin InhibitorsAngiotensin receptor neprilysin inhibitorsHeart failureHypertensionNatriuretic peptide systemNeprylisinRenin–angiotensin–aldosterone system

Identifiers

PMID27796865
OpenAlexW2540191715

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.